Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+9.6%
5Y CAGR+20.1%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+9.6%/yr
vs +15.5%/yr prior
5Y CAGR
+20.1%/yr
Recent deceleration
Acceleration
-6.0pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$15.79M+30.8%
2024$12.08M-9.4%
2023$13.33M+11.1%
2022$12.00M+48.6%
2021$8.08M+28.0%
2020$6.31M+23.6%
2019$5.10M-24.2%
2018$6.73M-26.5%
2017$9.15M-1.2%
2016$9.27M-